Cost-Effectiveness Analysis of Camrelizumab Plus Rivoceranib Versus Sorafenib as a First-Line Therapy for Unresectable Hepatocellular Carcinoma in the Chinese Health Care System
W.J. Lang, Lian Deng, Bei Huang, Dongmei Zhong, Gaofeng Zhang, Meijun Lu, Ming Ouyang
Topics & Concepts
MedicineSorafenibHepatocellular carcinomaCost effectivenessInternal medicineQuality-adjusted life yearOncologyCost-effectiveness analysisClinical trialRandomized controlled trialRisk analysis (engineering)Hepatocellular Carcinoma Treatment and PrognosisEconomic and Financial Impacts of CancerCancer Immunotherapy and Biomarkers